China-based InventisBio (Shanghai) has signed a 'Collaboration Agreement' with China-based Betta Pharma, it was reported on Friday.
According to the contract, InventisBio will out-license D-0316's right in China (including mainland China, Hong Kong and Taiwan) to Betta Pharma and is to co-develop this drug in China. Betta Pharma will have the exclusive commercialisation rights for the D-0316 product in the country.
The product is a third-generation EGFR-T790M tyrosine kinase inhibitor discovered and developed independently by InventisBio. It is mainly utilised for the treatment of EGFR-mutant non-small cell lung cancer. The drug is presently in phase one clinical trial in China. Betta Pharma will pay upfront and R&D milestones to InventisBio worth RMB230m. After the product is marketed commercially, Betta Pharma will pay various sales milestones and tiered royalties based on annual sales.
AstraZeneca reports meeting of primary end point by Calquence phase III ELEVATE-TN trial
AstraZeneca reports detailed results of Lynparza from phase 111 POLO trial
AstraZeneca reveals three-year overall survival results from Imfinzi Phase III PACIFIC trial
Ethris names Thomas Langenickel, MD as CMO
Cantargia announces presentation of phase I clinical data on antibody CAN04 at ASCO Annual Meeting